After calling for a major discount for Pfizer’s popular transthyretin amyloid cardiomyopathy (ATTR-CM) med tafamidis, a U.S.
TD Cowen raised the firm’s price target on Alnylam (ALNY) to $371 from $282 and keeps a Buy rating on the shares. The firm updated its ...
Sep. 25, 2024 — Almost everyone knows about HIV. Fewer people know about its relative, HTLV-1. However, HTLV-1 can cause serious illnesses, including cancer. To develop ways to combat this virus ...
Scotiabank started coverage on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) in a research note issued to ...
New data released by Merck suggests AstraZeneca and Sanofi’s Beyfortus, the monoclonal antibody injection that protects ...
Alnylam's Yvonne Greenstreet, at #STATSummit, predicts vutrisiran will become multibillion-dollar product for ...
Terray Therapeutics has raked in $120 million for a series B fundraise as the AI-focused biotech aims to transform small ...
Zacks.com on MSN4d
Alnylam Stock Up on Cardiomyopathy Drug Regulatory Filing in the EUAlnylam Pharmaceuticals ALNY announced that it has submitted a Type II Variation to the European Medicines Agency for ...
Fintel on MSN4d
Scotiabank Initiates Coverage of Alnylam Pharmaceuticals (ALNY) with Sector Outperform RecommendationFintel reports that on October 16, 2024, Scotiabank initiated coverage of Alnylam Pharmaceuticals (NasdaqGS:ALNY) with a ...
Several companies are developing new drugs treat transthyretin amyloidosis cardiomyopathy (ATTR-CM), an formerly obscure ...
While Judo Bio was preparing for its public launch, so was another siRNA start-up. City Therapeutics, the latest project of ...
Livforsakringsbolaget Skandia Omsesidigt raised its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback